Ischemic mitral regurgitation: when should one intervene?
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
18
9
2021
medline:
29
6
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
Optimal timing of intervention for ischemic mitral regurgitation remains to be elucidated. This review summarizes the data on the management of ischemic mitral regurgitation, and their implications on current practice and future research. Mechanistically, ischemic mitral regurgitation can present as Type I, Type IIIb or mixed Type I and IIIb disease. Severity of mitral regurgitation is typically quantified with echocardiography, either transthoracic or transesophageal echocardiography, but may also be assessed via cardiac MRI. In patients with moderate ischemic mitral regurgitation, revascularization can lead to left ventricular reverse remodeling in some. In patients with severe ischemic mitral regurgitation, mitral valve replacement may be associated with fewer adverse events related to heart failure and cardiovascular readmissions, compared with valve repair, although reverse remodeling may be better in patients following successful mitral repair. Transcatheter edge-to-edge repair also further complements the treatment of ischemic mitral regurgitation. A tailored approach to patients should be considered for each patient presenting with ischemic mitral regurgitation.
Identifiants
pubmed: 34535004
doi: 10.1097/HCO.0000000000000916
pii: 00001573-202111000-00013
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-763Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
de Marchena E, Badiye A, Robalino G, et al. Respective prevalence of the different Carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development. J Card Surg 2011; 26:385–392.
Acker MA, Parides MK, Perrault LP, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014; 370:23–32.
Perrault LP, Moskowitz AJ, Kron IL, et al. Optimal surgical management of severe ischemic mitral regurgitation: to repair or to replace? J Thorac Cardiovasc Surg 2012; 143:1396–1403.
Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018; 137:e67–e492.
Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res 2015; 46:328–338.
Pellizzon GG, Grines CL, Cox DA, et al. Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol 2004; 43:1368–1374.
Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation 2003; 108:1713–1717.
Grigioni F, Detaint D, Avierinos JF, et al. Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J Am Coll Cardiol 2005; 45:260–267.
Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103:1759–1764.
Michler RE. Learning from controversy: management of severe ischemic mitral regurgitation at the time of CABG. Ann Thorac Surg 2019; 108:321–323.
Michler RE, Smith PK, Parides MK, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2016; 374:1932–1941.
Nappi F, Antoniou GA, Nenna A, et al. Treatment options for ischemic mitral regurgitation: a meta-analysis. J Thorac Cardiovasc Surg 2020; S0022-5223(20)31262-9.
Hadjadj S, Marsit O, Paradis JM, Beaudoin J. Pathophysiology, diagnosis and new therapeutic approaches for ischemic mitral regurgitation. Can J Cardiol 2021; 37:968–979.
O’Gara PT, Mack MJ. Secondary mitral regurgitation. N Engl J Med 2020; 383:1458–1467.
Ailawadi G, Lim DS, Mack MJ, et al. One-year outcomes after MitraClip for functional mitral regurgitation. Circulation 2019; 139:37–47.
Carpentier A. Cardiac valve surgery – the ‘French correction’. J Thorac Cardiovasc Surg 1983; 86:323–337.
Bonow RO, O’Gara PT, Adams DH, et al. 2020 Focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 75:2236–2270.
Utsunomiya H, Itabashi Y, Kobayashi S, et al. Comparison of mitral valve geometrical effect of percutaneous edge-to-edge repair between central and eccentric functional mitral regurgitation: clinical implications. Eur Heart J Cardiovasc Imaging 2019; 20:455–466.
Marsit O, Clavel MA, Côté-Laroche C, et al. Attenuated mitral leaflet enlargement contributes to functional mitral regurgitation after myocardial infarction. J Am Coll Cardiol 2020; 75:395–405.
Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 2016; 374:344–353.
Kron IL, Hung J, Overbey JR, et al. Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation. J Thorac Cardiovasc Surg 2015; 149:752–761.e1.
Gammie JS, Quinn RW, Strauss ER, et al. Initial clinical experience with mitral valve translocation for secondary mitral regurgitation. Ann Thorac Surg 2021; [Epub ahead of print].
Pausch J, Sequeira Gross T, Müller L, et al. Subannular repair for functional mitral regurgitation type IIIb in patients with ischaemic versus dilated cardiomyopathy. Eur J Cardiothorac Surg 2021; 60:122–130.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 77:450–500.
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017; 30:303–371.
Grayburn PA, Carabello B, Hung J, et al. Defining ‘severe’ secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol 2014; 64:2792–2801.
Ben Zekry S, Nagueh SF, Little SH, et al. Comparative accuracy of two- and three-dimensional transthoracic and transesophageal echocardiography in identifying mitral valve pathology in patients undergoing mitral valve repair: initial observations. J Am Soc Echocardiogr 2011; 24:1079–1085.
Chinitz JS, Chen D, Goyal P, et al. Mitral apparatus assessment by delayed enhancement CMR: relative impact of infarct distribution on mitral regurgitation. JACC Cardiovasc Imaging 2013; 6:220–234.
Delgado V, Yedidya I. Assessment of secondary mitral regurgitation: is cardiovascular magnetic resonance 1-stop shop imaging technique? JACC Cardiovasc Imaging 2021; 14:840–842.
Shamam YM, De Jesus O. Nephrogenic systemic fibrosis. 2021; Treasure Island, FL: StatPearls, StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.
Doig F, Lu ZQ, Smith S, Naidoo R. Long term survival after surgery for ischaemic mitral regurgitation: a single centre Australian experience. Heart Lung Circ 2021; 30:612–619.
Ji Q, Zhao Y, Shen J, et al. Predictors of ischemic mitral regurgitation improvement after surgical revascularization plus mitral valve repair for moderate ischemic mitral regurgitation. J Cardiac Surg 2020; 35:528–535.
Takagi H, Umemoto T. Similar survival after repair vs replacement for ischemic mitral regurgitation. Semin Thorac Cardiovasc Surg 2016; 28:748–756.
Wang X, Zhang B, Zhang J, et al. Repair or replacement for severe ischemic mitral regurgitation: a meta-analysis. Medicine (Baltimore) 2018; 97:e11546.
Deja MA, Malinowski M, Widenka K, et al. Repair or replacement for secondary mitral regurgitation: results from polish national registry. Ann Thorac Surg 2021; [Epub ahead of print].
Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2014; 371:2178–2188.
Chan V, Ruel M, Mesana TG. Mitral valve replacement is a viable alternative to mitral valve repair for ischemic mitral regurgitation: a case-matched study. Ann Thorac Surg 2011; 92:1358–1365. discussion 65–66.
Dufendach K, Aranda-Michel E, Sultan I, et al. Outcomes of mitral valve surgery for severe ischemic mitral regurgitation. J Card Surg 2020; 35:390–396.
Ruel M, Chan V, Bédard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age. Circulation 2007; 116: (11 Suppl): I294–I300.
Magne J, Pibarot P, Dagenais F, et al. Preoperative posterior leaflet angle accurately predicts outcome after restrictive mitral valve annuloplasty for ischemic mitral regurgitation. Circulation 2007; 115:782–791.
Chan V, Levac-Martinho O, Sohmer B, et al. When should the mitral valve be repaired or replaced in patients with ischemic mitral regurgitation? Ann Thorac Surg 2017; 103:742–747.
Ciarka A, Braun J, Delgado V, et al. Predictors of mitral regurgitation recurrence in patients with heart failure undergoing mitral valve annuloplasty. Am J Cardiol 2010; 106:395–401.
Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379:2307–2318.
Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018; 379:2297–2306.
Mack MJ, Lindenfeld J, Abraham WT, et al. 3-Year outcomes of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol 2021; 77:1029–1040.
Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail 2019; 21:1619–1627.
Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 2019; 12:353–362.
Goel K. Secondary MR: how has the COAPT trial changed our approach? 2019.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995–2008.